Related Experiment Videos

Optimizing treatment of diabetes and cardiovascular disease with combined alpha,beta-blockade

David S H Bell1

  • 1Division of Endocrinology, Department of Medicine, University of Alabama Medical School, Birmingham, AL 35294, USA. dshbell@uab.edu

Current Medical Research and Opinion
|August 9, 2005
PubMed

Insights

Newer beta-blockers offer significant cardiovascular protection for diabetic patients without adverse metabolic effects. These medications can be safely used in patients with diabetes and heart failure, improving outcomes.

Area of Science:

  • Cardiology
  • Diabetology
  • Pharmacology

Background:

  • Diabetic patients face high cardiovascular risk, comparable to non-diabetics post-myocardial infarction.
  • Beta-blockers are proven cardiovascular risk reducers but are underutilized in diabetes due to metabolic concerns.
  • Physicians hesitate to prescribe beta-blockers for diabetics despite their enhanced efficacy in this population.

Purpose of the Study:

  • Review the link between diabetes and cardiovascular risk factors.
  • Describe metabolic consequences of insulin resistance.
  • Discuss beta-blocker impact on cardiovascular disease in diabetic patients.

Main Methods:

  • Medline literature search conducted up to December 2004.
  • Review of studies on beta-blocker use in diabetic patients.
  • Analysis of metabolic and cardiovascular outcomes.

Main Results:

  • Beta-blockers provide substantial cardioprotection in diabetes.
  • Some beta-blockers carry metabolic risks; newer agents mitigate these.
  • Vasodilating, nonselective beta-blockers show neutral metabolic and lipid profiles, not promoting insulin resistance.
  • These newer agents are safe for heart failure patients with diabetes.

Conclusions:

  • Nonselective vasodilating beta-blockers, like carvedilol, are suitable for cardiovascular disease in diabetic patients.
  • These agents avoid the negative metabolic consequences of older beta-blockers.
  • Safe and effective cardiovascular risk management is achievable in diabetics using specific beta-blockers.
Abstract

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...